WGS GeneDx Holdings Corp. Insider Trading

Casdin Capital (Director) purchased 500,000 shares over 3 days for $21,459,735.50 at blended $42.92, now -73.8% from 52-week high.

Casdin Capital executed three separate open-market purchases totaling 500,000 shares for $21,459,735.50 between May 18–20, 2026, increasing holdings from 3,007,164 to 3,507,164 shares (+16.6%). The purchases occurred at $42.55, $42.60, and $43.81, establishing a blended average of $42.92—yet the stock now trades at $44.73, still down 73.8% from its 52-week high of $170.87 and down 35.8% in 30 days. Within the SAME-TICKER HISTORY at WGS, prior timing patterns are favorable (4 of 5 prior trades well-timed at the 90-day mark), including four prior buys with 90-day returns of +41.9%, +53.4%, +67.8%, and +72.7%, though the most recent activity was a sell on 2025-08-22 that yielded only +7.2% and +10.9% returns. The company remains unprofitable with net income of $-63,316,000.00 against quarterly revenue of $102,254,000.00, despite 40.0% annual revenue growth. The substantial dollar commitment ($21.5M) and multi-day accumulation pattern against sharply depressed valuation (down 50.7% over 90 days) warrant close monitoring of fundamental inflection signals.

Director Meister buys 351,273 shares across 6 trades for $13.8M (avg $39.19) as stock falls 76.2% from 52-week high

Director Keith A. Meister executed 6 separate open-market purchases totaling 351,273 shares for $13,765,344.69 over three days (May 13–15, 2026), raising his holdings from 4,433,297 to 4,784,570 shares. The purchases occurred as the stock was in sharp decline, trading at $40.75 currently, which is -76.2% from the 52-week high of $170.87, and down -39.6% over the prior 30 days and -54.8% over 90 days. Across his 5 prior trades at WGS, Meister's timing outcomes were mixed: only 2 of 5 prior buys yielded positive 90-day returns. The company is unprofitable with net income of $-63,316,000.00 against revenue of $102,254,000.00 (latest quarter), though it shows annual revenue growth of +40.0%. The scale and timing of this multi-transaction purchase in a volatile, unprofitable biotech context warrant attention to underlying company conditions and Meister's conviction in the recovery thesis.

Director Meister acquires over 1.2M shares across 13 transactions; stock down 76% from 52-week high amid unprofitable operations and poor timing history at this ticker.

Keith Meister, a director and 10% beneficial owner of GeneDx, deployed substantial capital across 13 open-market purchases in early May, acquiring over 1.2 million shares at prices ranging from the mid-$35s to low-$41s. The stock is trading well below its 52-week high and has declined significantly over recent months, creating a classic "buying the dip" scenario. However, Meister's track record at this specific company is concerning: all five of his prior purchases at GeneDx in March yielded substantial subsequent declines over both the 30-day and 90-day periods that followed, and his broader insider track record across all securities shows minimal success with open-market buys. Additionally, GeneDx remains unprofitable with operating losses in its latest quarter despite year-over-year revenue growth, raising questions about whether the steep discount reflects genuine value or deteriorating fundamentals. This filing is notable primarily as a test of whether an insider with a poor historical timing record can successfully identify a bottom in a stock already down substantially from recent highs.